Recent

% | $
Quotes you view appear here for quick access.

Aeterna Zentaris Inc. Message Board

  • rocksau1970 rocksau1970 Feb 23, 2012 8:35 AM Flag

    @Franwurl: "They" changed the QT study

    From:
    "To evaluate the safety profile (adverse events) and efficacy (response rate, and time to progression) of all study patients treated with perifosine"

    TO:
    "- To evaluate the safety profile (adverse events) and efficacy (response rate, and time to progression) of all study patients treated with perifosine.
    - After Day 24, to evaluate the safety profile (adverse events) and efficacy (response rate and time to progression) of all study patients who remain on single agent perifosine, switch to the combination of capecitabine + perifosine or switch to the combination of sorafenib+perifosine."

    look here: http://clinicaltrials.gov/archive/NCT01224730/2012_02_06/changes

    info: sorafenib (Nexavar): made by BAYER against rcc and hcc

    Perifosine and sorafenib against hcc - an new combination?

    any idea why?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Thanks for asking. I have been in Asia the last several weeks and have only occasionally been able to access the Internet with reasonable speed.

      My strong suspicion is that AEZS wishes to start exploring P in combination with other agents in a manner that Roche has done with Xeloda. The chances are high that other effective combinations will be found for P in treating various cancers.

      My strong opinion is that PCAP has already been effective beyond a 2 month level over Xeloda + Placebo. We just need to wait now for final results to confirm my opinion.

      Try to ignore the pps that does not in any manner reflect the inherent value in this company.

      Franwurl
      Sihanoukville, Cambodia

    • I don't know if this will help Perifosone get approved, although I believe that it SHOULD. But I LOVE that this drug is perceived as, and may in fact BE, a drug that works wonders when combined with other drugs. There may be a drug combo out there, X+ Perifosine that is HYPER-effective on a particular indication/cancer type. With it's toxicity profile, if approved it could be tried with anything and everything. Not probably but possible you can find the right combo that hits a home run. To me this is the reason why it MIGHT achieve the most bullish expectations in efficacy and the stock AEZS achieve the most bullish price targets. If may be way off but if so would appreciate hearing why. I actually like being corrected why I'm being TOO bullish.

 
AEZS
0.186-0.013(-6.72%)Jul 29 3:59 PMEDT